Self-reported health in people with Parkinson's disease left untreated at diagnosis

Editorial

Peter Hagell. J Neurol Neurosurg Psychiatry. 2007 May.

. 2007 May;78(5):442.

doi: 10.1136/jnnp.2006.109454. Epub 2006 Nov 29.

Abstract

Early initiation of treatment in Parkinson's disease prevents patient‐reported deteriorations, but what is gained?

Competing interests: None.

A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.
Grosset D, Taurah L, Burn DJ, MacMahon D, Forbes A, Turner K, Bowron A, Walker R, Findley L, Foster O, Patel K, Clough C, Castleton B, Smith S, Carey G, Murphy T, Hill J, Brechany U, McGee P, Reading S, Brand G, Kelly L, Breen K, Ford S, Baker M, Williams A, Hearne J, Qizilbash N, Chaudhuri KR. Grosset D, et al. J Neurol Neurosurg Psychiatry. 2007 May;78(5):465-9. doi: 10.1136/jnnp.2006.098327. Epub 2006 Nov 10. J Neurol Neurosurg Psychiatry. 2007. PMID: 17098846 Free PMC article.

1. Grosset D, Taurah L, Burn D J.et al A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 200778465–469. - PMC - PubMed
1. Schapira A H V, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 200659559–562. - PubMed
1. Aminoff M J. Treatment should not be initiated too soon in Parkinson's disease. Ann Neurol 200659562–564. - PubMed
1. Marras C, Lang A E. Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. Expert Rev Neurother 20044985–993. - PubMed
1. Food and Drug Administration Draft guidance for industry on patient‐reported outcome measures: use in medicinal product development to support labeling claims. Federal Regist 2006715862–5863.